Martin Brenner

Company: iBio

Job title: Chief Executive & Chief Scientific Officer

Seminars:

Targeting the TGF-Beta Superfamily With Extended Half-Life Antibodies to Enable Improved Quality of Weight Loss 4:10 pm

Long half life antibodies can reduce dose volume and frequency without sacrificing efficacy Inhibition of myostatin can counter lean mass loss and potentially enable improved patient experience and outcomes Additional targets and combinations of targets within the TGF-beta superfamily can enable further improvements in weight loss qualityRead more

day: Day One